-
CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline
•
China-based CStone Pharmaceuticals (HKG: 2616) reported its 2024 financial results and recent business highlights. Revenues reached RMB 407.2 million (USD 56.1 million), a 12.2% year-on-year (YOY) decrease. This consisted of RMB 175 million (USD 24.1 million) in pharmaceutical product sales and RMB 232 million (USD 32 million) in license fee…
-
Lee’s Pharmaceutical Holdings Ltd Reports 32.9% Revenue Growth in 2023
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) released its 2023 financial report, recording HKD 1.4 billion (USD 193 million) in revenues, up 32.9% year-on-year (YOY). Licensed products continued to yield significant sales growth with HKD 553 million (USD 76 million), accounting for 39.5% of the total revenue. Patented and generic…
-
RemeGen’s 2024 Revenue Soars 58.54% on Strong Product Sales and R&D Growth
•
China-based biotech RemeGen Co., Ltd (HKG: 9995, SHA: 688331) released its 2024 financial report, recording RMB 1.717 billion (USD 236.3 million) in revenues, a 58.54% year-on-year (YOY) increase. Product sales reached RMB 1.699 billion (USD 233.9 million), up 61.9% YOY. The annual loss decreased by 2.8% YOY to RMB 1.468…
-
JW Therapeutics Sees 9% Revenue Decline in 2024 Amid Commercial Strategy Shift
•
China-based JW Therapeutics (HKG: 2126) released its 2024 financial report, recording RMB 158.2 million (USD 21.8 million) in revenue, a 9% year-on-year (YOY) decline. This decrease was primarily due to the implementation of a commercial activity optimization strategy in the second half of 2024 and a business personnel organizational efficiency…
-
Ascentage Pharma’s Revenue Soars 342% in 2024 on Strong Drug Sales and Partnerships
•
China-based Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855) unveiled its 2024 financials, showing revenues skyrocketing 342% year-on-year (YOY) to RMB980 million (USD135 million). This remarkable growth was primarily driven by an option payment from Japanese partner Takeda and robust sales of olverembatinib, the novel BCR-ABL1 tyrosine kinase inhibitor (TKI),…
-
Shanghai Pharmaceuticals Reports 5.75% Revenue Growth in 2024 with Innovation Initiatives
•
China’s Shanghai Pharmaceuticals (SPH; SHA: 601607, HKG: 2607) released its 2024 financial results, showing total revenues up 5.75% year-on-year (YOY) to RMB 275.251 billion (USD 37.9 billion). Pharmaceutical industry and business sales reached RMB 22.731 billion (USD 3.3 billion) and RMB 251.5 billion (USD 34.6 billion) respectively, with the latter…
-
Luye Pharma’s Shandong Boan Bio Reports 17.5% Revenue Growth in 2024
•
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd (HKG: 6955) released its 2024 financial report, showing revenues growing 17.5% year-on-year (YOY) to RMB726.3 million (USD100 million). This growth was primarily driven by BA1101, a biosimilar of Roche’s Avastin (bevacizumab), and BA6101, a version of Amgen’s…
-
MicroPort CardioFlow Medtech Reports 7.5% Revenue Growth in 2024 Driven by Global Expansion
•
China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) announced its 2024 financial report, recording RMB362 million (USD50 million) in revenue, a 7.5% year-on-year (YOY) increase. This growth was driven by the ongoing global commercialization of its flagship products, VitaFlow Liberty and Alwide Plus. The period also saw the official launch…
-
MicroPort MedBot Reports Strong 2024 Growth for Toumai and SkyWalker Robots
•
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) revealed its 2024 financial performance, recording RMB257 million (USD35 million) in revenues, a 146% year-on-year (YOY) increase. This growth was driven by the commercialization of the Toumai Laparoscopic Surgical Robot and SkyWalker Orthopedic Surgical Robot both domestically and internationally. Despite the revenue…
-
China Resources Medical Holdings Reports 2024 Revenue of RMB9.86 Billion Amid Net Profit Surge
•
China Resources Medical Holdings Company Ltd (CR Medical, HKG: 1515) has published its 2024 financial report. The company recorded revenues of RMB 9.86 billion (USD 1.4 billion), marking a 2.5% year-on-year (YOY) decrease. Despite the revenue decline, net profits rose significantly by 104.9% YOY to RMB 672 million (USD 92.5…
-
WuXi Biologics Reports 9.6% Revenue Growth in 2024, Expanding CRDMO Services
•
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has released its 2024 financial report, recording revenues of RMB 18.68 billion (USD 2.57 billion) after a 9.6% year-on-year (YOY) increase. Non-COVID revenue grew by 13.1% YOY, driven by successful execution of the company’s strategies, expanded service offerings,…
-
Fosun Pharma’s 2024 Revenue Reaches RMB 41.1 Billion Amid R&D Investment
•
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its 2024 financial report, recording revenues of RMB 41.1 billion (USD 5.7 billion), a slight decrease of 0.80% year-on-year (YOY). The net profit attributable to the parent company reached RMB 2.77 billion (USD 381 million), marking a…
-
Burning Rock Reports Q4 Revenue Growth Amid Improved Profitability
•
Guangzhou-based medical device company Burning Rock (NASDAQ: BNR) has released its Q4 2024 financial results. The company reported Q4 revenues of RMB 126 million (USD 17.3 million), representing a 4.1% year-on-year (YOY) increase. For the full year, revenues reached RMB 515.8 million (USD 71 million), a 4.0% YOY decrease. Despite…
-
Alphamab Oncology Reports 192.58% Revenue Surge Led by Envafolimab
•
Alphamab Oncology (HKG: 9966) has announced its 2024 financial results, marking a significant milestone with its first annual profit. The company reported revenues of RMB 640.08 million (USD 88.1 million), representing a 192.58% year-on-year increase. Profits reached RMB 166.34 million (USD 22.9 million), driven primarily by sales of its core…
-
Everest Medicines Reports Surge in Revenue, Advances Core Products and R&D Pipeline
•
China-based Everest Medicines (HKG: 1952) has announced its 2024 financial results, marking a significant milestone in its growth trajectory. The company reported a remarkable 461% year-on-year increase in revenues, reaching RMB 707 million (USD 97 million). Concurrently, the non-IFRS net loss narrowed by 25% to RMB 537.6 million (USD 74…
-
Simcere Pharmaceutical Group Reports Steady Revenue Amid R&D Investment Shift
•
China-based Simcere Pharmaceutical Group (HKG: 2096) has released its 2024 financial performance report, recording RMB 6.6 billion (USD 914 million) in revenues over the 12 months, marking a 0.4% year-on-year (YOY) increase. The profit attributable to equity shareholders rose by 2.6% YOY to RMB 733 million (USD 101 million). Notably,…
-
Henlius Biotech Reports 6.1% Revenue Growth with Strong Oncology Product Sales
•
Shanghai Henlius Biotech Inc. (HKG: 2696) has published its 2024 financial results, recording revenues of RMB 5.72 billion (USD 788 million), representing a 6.1% year-on-year (YOY) increase. Net profits reached RMB 820.5 million (USD 114 million), up 50.3% YOY, reflecting strong performance across its product portfolio. Core Product PerformanceHenlius Biotech…
-
Sichuan Kelun-Biotech Reports 25.5% Revenue Growth with Key Drug Approvals
•
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has released its 2024 financial report, recording revenues of RMB 1.933 billion (USD 266 million), representing a 25.5% year-on-year (YOY) increase. This growth includes USD 147.5 million in cooperation payments from US partner Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK), UK-based…
-
WuXi XDC Reports 90.8% Revenue Surge, Expanding in ADC Market
•
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA (a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259)), has released its 2024 financial report. The company achieved RMB 4.52 billion (USD 558 million) in revenue for the full year, marking a 90.8% year-on-year (YOY)…
-
Hansoh Pharmaceutical Reports 21% Revenue Growth, Boosted by Innovative Drugs
•
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) released its 2024 financial report last week, recording revenues of RMB 12.26 billion (USD 1.69 billion) after a 21.3% year-on-year (YOY) expansion. The main growth drivers, innovative drugs and collaborative products, generated combined sales of RMB 9.48 billion (USD 1.31 billion), up…
